ArticleFrontiers in immunology2025

Real-world efficacy and safety of disitamab vedotin monotherapy or in combination with PD-1 inhibitors in locally advanced or metastatic upper tract urothelial carcinoma: a multicenter retrospective study.

Shuaipeng He et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.